An estimated 4.5% of total US health care dollars have been devoted to mitigating chronic rhinosinusitis. The most recalcitrant of these patients undergo surgery, which fails to improve symptoms in approximately 25% of patients. Recent advances in informational, microbiomic, and genomic analysis have introduced the first set of tools that patients, physicians, politicians, and payers can apply to better forecast which patients will respond favorably to endoscopic sinus surgery. This article summarizes the forces driving the application of personalized medicine to CRS and how new advances can be applied to clinical practice.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.otc.2016.08.003 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!